BiomX Inc.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Gaithersburg, MD.

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share.

BiomX Announces a Mandatory Unit Separation

PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept.

BiomX Stock Gains From Favorable Study Data Presentation on BX004

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections.

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

BiomX Inc. (NYSE:PHGE ) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Yale Jen - Laidlaw & Company Farhana Sakloth - Ladenburg Thalmann Operator Greetings, and welcome to BiomX Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it intends to effect a one-for-ten reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Common Stock will continue to trade on the NYSE American under the existing symbol “PHGE” and will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 09090D 301.

BiomX Inc. Announces 1-for-10 Reverse Stock Split

BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading pha ge therap y pipeline

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, August 15, 2024, at 8:00 a.m.

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

DexCom

Edwards Lifesciences

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `

Top 3 Health Care Stocks That May Explode In Q3

GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received a notification (the “Acceptance Letter”) from the NYSE American LLC (the “NYSE American”), dated July 23, 2024, stating that the NYSE American has accepted the Company's previously submitted plan to regain compliance with the NYSE American's listing standards (the “Plan”). In the Acceptance Letter, the NYSE American confirmed that it has granted the Company until November 23, 2025 (the “Plan Period”) to regain compliance with the continued listing standards. As previously disclosed, on May 23, 2024, BiomX received a deficiency letter from the NYSE American indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Company Guide”).

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company's stockholders have voted to approve a proposal to convert BiomX's outstanding Series X Non-Voting Convertible Preferred Stock (“Series X Preferred Stock”) into shares of BiomX's common stock. The result of the vote was previously disclosed in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 9, 2024.

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification (“the Notice”) from the NYSE American LLC (“NYSE American”), dated May 23, 2024, stating that the Company is no longer in compliance with continued listing standards, as set forth in Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”).

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present at two upcoming conferences data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in an oral presentation and an ePoster at the 47th European Cystic Fibrosis Conference, which is taking place June 5-8, 2024, in Glasgow, United Kingdom, and in a Rapid Fire oral presentation and a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-17, 2024, in Atlanta, Georgia.

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

BiomX Inc. (NYSE:PHGE ) Q1 2024 Earnings Conference Call May 21, 2024 8:00 AM ET Company Participants Jonathan Solomon - Chief Executive Officer Avi Gabay - Chief Financial Officer Conference Call Participants Joe Pantginis - HC Wainwright Yale Jen - Laidlaw & Co. Sohanna - Ladenburg Thalmann Operator Hello and welcome to the BiomX first quarter 2024 financial results. If anyone should require Operator assistance, please press star, zero on your telephone keypad.

BiomX (PHGE) Q1 2024 Earnings Call Transcript

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Tuesday, May 21, 2024, at 8:00 a.m. ET, to report first quarter 2024 financial results and provide business and program updates.

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024 Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board.

BiomX Announces the Appointment of Susan Blum to its Board of Directors

BiomX (PHGE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission on April 4, 2024, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's 2023 audited financial statements or to its 2023 annual report on Form 10-K.

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

BiomX Inc. (NYSE:PHGE ) Q4 2023 Earnings Conference Call April 3, 2024 8:00 AM ET Company Participants Avi Gabay - Interim CFO Jonathan Solomon - CEO Conference Call Participants Joseph Pantginis - H.C. Wainwright Operator Good morning, and welcome to the BiomX Full Year 2023 Financial Results and Corporate Update Conference Call.

BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript

Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, April 3rd, 2024, at 8:00 a.m. ET, to report fourth quarter and full year 2023 financial results and a provide business update.

News for BiomX Inc. Stock (PHGE)